| Active Not Recruiting | Clear Cell Chondrosarcoma in Italy NCT07360964 | Istituto Ortopedico Rizzoli | N/A |
| Recruiting | PET-imaging of Two Vartumabs in Patients With Solid Tumors NCT06645808 | Var2 Pharmaceuticals | EARLY_Phase 1 |
| Not Yet Recruiting | Understanding Engagement Trends in Chondrosarcoma Clinical Trials NCT06029478 | Power Life Sciences Inc. | — |
| Recruiting | A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning NCT06387485 | Ricoh USA, Inc. | N/A |
| Recruiting | Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy NCT06029218 | Centre Antoine Lacassagne | N/A |
| Recruiting | Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base NCT05861245 | Quironsalud | N/A |
| Unknown | A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma NCT05193188 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Recruiting | Adherence to a Personalized Home Exercise Program in Patients With Bone Tumor Undergoing Lower Extremity Salva NCT05779670 | Istituto Ortopedico Rizzoli | — |
| Recruiting | Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone NCT05033288 | Mayo Clinic | — |
| Recruiting | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | The Registry of Oncology Outcomes Associated With Testing and Treatment NCT04028479 | Taproot Health | — |
| Recruiting | A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors NCT04673942 | EpicentRx, Inc. | Phase 2 |
| Recruiting | Image Assisted Optimization of Proton Radiation Therapy in Chordomas and Chondrosarcomas NCT04832620 | Leiden University Medical Center | — |
| Active Not Recruiting | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations NCT04521686 | Eli Lilly and Company | Phase 1 |
| Terminated | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, NCT04553692 | IGM Biosciences, Inc. | Phase 1 |
| Active Not Recruiting | AG-120 in People With IDH1 Mutant Chondrosarcoma NCT04278781 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sar NCT04055220 | Centre Leon Berard | N/A |
| Recruiting | Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration NCT04040205 | Medical College of Wisconsin | Phase 2 |
| Recruiting | Long-Term Longitudinal QoL in Patients Undergoing EEA NCT04087902 | Ohio State University | — |
| Recruiting | Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas NCT03442465 | Memorial Sloan Kettering Cancer Center | — |
| Unknown | A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma NCT02982486 | Assaf-Harofeh Medical Center | Phase 2 |
| Active Not Recruiting | Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial NCT03173976 | Mohammed Milhem | Phase 1 |
| Completed | Low Grade Chondrosarcoma Versus Enchondroma NCT02996747 | Istituto Ortopedico Rizzoli | — |
| Completed | Metformin And Chloroquine in IDH1/2-mutated Solid Tumors NCT02496741 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 1 / Phase 2 |
| Completed | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or An NCT02273739 | Celgene | Phase 1 / Phase 2 |
| Suspended | A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas NCT02008019 | Centre Leon Berard | Phase 2 |
| Completed | Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mut NCT02073994 | Institut de Recherches Internationales Servier | Phase 1 |
| Completed | Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors NCT01560260 | National Cancer Institute (NCI) | Phase 2 |
| Completed | IPI-926 Extension Protocol for Continuation of Treatment With IPI-926 NCT01609179 | Infinity Pharmaceuticals, Inc. | N/A |
| Unknown | Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum NCT02587169 | Broto, Javier Martín, M.D. | Phase 1 / Phase 2 |
| Completed | Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI NCT01336803 | Heike E Daldrup-Link | Phase 2 |
| Completed | Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma NCT01330966 | Emerald Clinical Inc. | Phase 2 |
| Unknown | Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Low and Inter-mediate Grade Chondrosarcom NCT01182753 | Heidelberg University | Phase 3 |
| Completed | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced NCT01154452 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery NCT01553539 | Wake Forest University Health Sciences | Phase 2 |
| Terminated | A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g) NCT00543712 | Genentech, Inc. | Phase 2 |
| Completed | Trial of Dasatinib in Advanced Sarcomas NCT00464620 | Sarcoma Alliance for Research through Collaboration | Phase 2 |
| Active Not Recruiting | Proton Beam Therapy for Chondrosarcoma NCT00496522 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymph NCT00004241 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine NCT00592748 | Massachusetts General Hospital | Phase 1 / Phase 2 |
| Terminated | S9624 Ifosfamide in Treating Patients With Meningeal Tumors NCT00003292 | SWOG Cancer Research Network | Phase 2 |
| Available | BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast NCT04091295 | Aveni Foundation | — |
| No Longer Available | Tazemetostat Expanded Access Program for Adults With Solid Tumors NCT03874455 | Epizyme, Inc. | — |